Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Initiator Pharma strengthens its management team – appoints Annette Säfholm as COO

INITPress release14.09.2026 klo 09.30

Initiator Pharma A/S today announced the appointment of Annette Säfholm, PhD, as Chief Operating Business Officer (COO) and a member of the management team. She will support the CEO in ongoing business development, partnering and strategic discussions, while contributing to key operational activities across the company.

The appointment strengthens Initiator Pharma’s business development and operational capabilities as the company advances its Phase IIa study of pudafensine in vulvodynia and prepares for topline results expected by the end of 2026.

“Partnering pudafensine is a core priority for Initiator Pharma. Annette brings extensive business development, operational and women’s health experience,” said Claus Elsborg Olesen, CEO of Initiator Pharma. “She will play an important role in advancing our partnering activities and strengthening execution as we approach a significant clinical milestone.”

Annette Säfholm has close to 20 years of life science experience across executive, business development and board roles. Most recently, she served as CEO of Gedea Biotech, leading the company from university spin-out through clinical development, EU MDR approval and commercial readiness.

“Pudafensine is a differentiated asset addressing major unmet needs in pain and sexual dysfunction,” said Annette Säfholm. “I look forward to working with Claus and the team to advance partnering discussions and support the company’s strategic and operational execution.”

About Annette Säfholm

Annette Säfholm has close to 20 years of experience in life science strategy, business development and company building. She served as CEO of Gedea Biotech from its formation in 2016 until 2026, advancing treatments for vaginal infections through six clinical studies and EU MDR approval.

She has previously held roles at Reccan Diagnostics and Idogen and co-founded WNT Research. She is a board member of Gedea Biotech and Swipp. Annette holds a PhD in Medicine from Lund University, a Master’s degree in Medical Biology from Linköping University and an executive management education for EFL Lund.

For additional information about Initiator Pharma, please contact:


Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma


Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of one clinical stage assets – pudafensine – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED.
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye Nordic Growth AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments


Initiator Pharma strengthens its management team – appoints Annette Säfholm as COO